Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19964077 | 0.75 | HRH3 (0.38) | HRH3CYP3A4 | |
| SCHEMBL17700603 | 0.74 | CYP3A4 (0.42) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL17700260 | 0.71 | CYP3A4 (0.43) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL18466077 | 0.71 | ALDH1A1 (0.35) | HRH3AR | |
| SCHEMBL22010700 | 0.69 | ALDH1A1 (0.46) | HRH3CYP3A4CYP2C9SLC22A6SLC22A8 | |
| SCHEMBL18595673 | 0.69 | SLC22A12 (0.45) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL24782865 | 0.67 | CYP3A4 (0.42) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL17700237 | 0.67 | SLC22A12 (0.41) | CYP3A4CYP2C9SLC22A12AR | |
| SCHEMBL2343338 | 0.66 | GABRA1 (0.44) | HRH3CYP3A4CYP2C9 | |
| SCHEMBL823824 | 0.65 | GABRA1 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | Epizyme, Inc. (US) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307413-B2 | Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof | PRMT5, PRMT1, PRMT3 | HRH3 629/4885CYP3A4 1668/4885CYP2C9 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.